未经证实:在处于高凝状态的年轻患者中,COVID-19的晚期诊断可导致高死亡率。COVID-19的临床表现包括呼吸和肺外症状,如高凝状态,转氨酶增加,和多器官衰竭。
未经评估:一名34岁男性高烧3天后出现在急诊室,弱点,还有胀气.该患者患有血小板减少症和肝转氨酶升高,最初被诊断为登革热出血热。他接受了水合静脉输液,氧气,退烧药,和肝脏保护者。第4天,患者被诊断为COVID-19,并接受了降低丙氨酸转氨酶和天冬氨酸转氨酶水平的治疗。在等待外包D二聚体和凝血酶原时间结果的同时,患者在第5天给予低分子量肝素(LMWH).在第13天,他的病情恶化,伴有头痛和呼吸急促,但患者家属拒绝插管。胸部CT扫描显示两肺有大的毛玻璃影。患者接受了额外的药物治疗,比如美罗培南,地塞米松,还有Remdesivir.第15天,病人去世了。
未经批准:在住院COVID-19患者中,与标准的深静脉血栓(DVT)预防相比,中等剂量LMWH的死亡率似乎更低。然而,由于COVID-19的晚期诊断,患者在治疗开始时未给予LMWH.
未经证实:高凝状态是COVID-19患者高死亡率的部分原因。早期发现和管理高凝状态,包括LMWH的使用,可以减轻COVID-19症状的严重程度。
UNASSIGNED: Late diagnosis of COVID-19 in young patients in a hypercoagulable state can cause a high mortality rate. Clinical manifestations of COVID-19 include respiratory and extrapulmonary symptoms such as a hypercoagulable state, increased transaminase enzymes, and multiple-organ failure.
UNASSIGNED: A 34-year-old male presented to the emergency room after 3 days of high fever, weakness, and flatulence. The patient had thrombocytopenia and elevated liver transaminase enzymes and was initially diagnosed with dengue hemorrhagic fever. He was given hydration intravenous fluids, oxygen, antipyretic, and hepatoprotector. On day 4, the patient was diagnosed with COVID-19 and received therapy to decrease the Alanine transaminase and Aspartate transaminase levels. While waiting for outsourced D dimer and prothrombin time results, the patient was given low molecular weight heparin (
LMWH) on day 5. On day 13, his condition deteriorated with cephalgia and shortness of breath, but the patient\'s family refused intubation. The chest CT scan revealed large ground-glass opacities in both lungs. The patient was given additional medications, such as Meropenem, Dexamethasone, and Remdesivir. On day 15, the patient passed away.
UNASSIGNED: Intermediate
LMWH dosage seems to be associated with a lower mortality incidence than standard Deep Vein Thrombosis (DVT) prophylaxis in hospitalized COVID-19 patients. However, due to the late COVID-19 diagnosis, the patient was not given
LMWH at the beginning of treatment.
UNASSIGNED: A hypercoagulable state is partly responsible for the high mortality rate of COVID-19 patients. Early detection and management of the hypercoagulable state, including the use of
LMWH, can decrease the severity of COVID-19 symptoms.